#BEGIN_DRUGCARD DB00845

# AHFS_Codes:
Not Available

# ATC_Codes:
J04BA01

# Absorption:
Absorption varies from 45 to 62% following oral administration in leprosy patients. Bioavailability is approximately 70%. Food increases bioavailability and rate of absorption.

# Biotransformation:
Hepatic. Three metabolites have been identified - two conjugated and one unconjugated, however, it is not yet known whether these metabolites are pharmacologically active. Metabolite I is formed by hydrolytic dehalogenation of clofazimine, metabolite II presumably is formed by a hydrolytic deamination reaction followed by glucuronidation, and metabolite III appears to be a hydrated clofazimine glucuronide.

# Brand_Mixtures:
Not Available

# Brand_Names:
Lampren
Lamprene

# CAS_Registry_Number:
2030-63-9

# ChEBI_ID:
3749

# Chemical_Formula:
C27H22Cl2N4

# Chemical_IUPAC_Name:
N,5-bis(4-chlorophenyl)-3-[(propan-2-yl)imino]-3,5-dihydrophenazin-2-amine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Antimycobacterials
Coloring Agents
Dyes
Leprostatic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
7.66

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
0.225 mg/L (virtually insoluble)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Clofazimine

# HET_ID:
Not Available

# Half_Life:
10 days following a single dose, 70 days after long-term, high-dose therapy.

# InChI_Identifier:
InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3/b30-24+

# InChI_Key:
InChIKey=WDQPAMHFFCXSNU-BGABXYSRSA-N

# Indication:
For the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.

# KEGG_Compound_ID:
C06915

# KEGG_Drug_ID:
D00278

# LIMS_Drug_ID:
845

# Mechanism_Of_Action:
Appears to preferentially bind to mycobacterial DNA leading to disruption of the cell cycle and eventually kills the bacterium. It may also bind to bacterial potassium transporters, thereby inhibiting their function. Lysophospholipids have been found to mediate the activity of this drug.

# Melting_Point:
210-212 Â°C

# Molecular_Weight_Avg:
473.396

# Molecular_Weight_Mono:
472.122152138

# Organisms_Affected:
Mycobacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164748759

# Pharmacology:
Clofazimine exerts a slow bactericidal effect on <i>Mycobacterium leprae</i> (Hansen's bacillus). Clofazimine inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. Clofazimine also exerts antiinflammatory properties in controlling erythema nodosum leprosum reactions. Clofazimine is highly lipophilic and tends to be deposited predominantly in fatty tissue and in cells of the reticuloendothelial system. It is taken up by macrophages throughout the body. Measurement of the minimum inhibitory concentration (MIC) of clofazimine against leprosy bacilli in vitro is not yet feasible. In the mouse footpad system, the multiplication of M.leprae is inhibited by introducing 0.0001%- 0.001% clofazimine in the diet. Although bacterial killing may begin shortly after starting the drug, it cannot be measured in biopsy tissues taken from patients for mouse footpad studies until approximately 50 days after the start of therapy.

# Predicted_LogP_Hydrophobicity:
7.39

# Predicted_LogS:
-5.5

# Predicted_Water_Solubility:
1.51e-03 g/l

# Primary_Accession_No:
DB00845

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic3/clofazimine.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00278

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Chlofazimine
Clofazimina [INN-Spanish]
Clofaziminum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Oral, rabbit: LD<sub>50</sub> = 3.3 g/kg; Oral, mouse: LD<sub>50</sub> = > 4 g/kg. Severe abdominal symptoms have necessitated exploratory laparotomies in some patients on clofazimine therapy. Rare reports have included splenic infarction, bowel obstruction, and gastrointestinal bleeding. Deaths have been reported, following severe abdominal symptoms.

# Update_Date:
2013-02-08 16:19:41 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Clofazimine

# pKa_Isoelectric_Point:
8.51

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7829710	Arbiser JL, Moschella SL: Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):241-7.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_1_General_Function:
Biological information storage and information transfer

# Drug_Target_1_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
874

# Drug_Target_1_Locus:
All loci

# Drug_Target_1_Molecular_Weight:
7656 (double strand)

# Drug_Target_1_Name:
DNA

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
1BNA

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Deoxyribonucleic acid

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16286358	Cholo MC, Boshoff HI, Steel HC, Cockeran R, Matlola NM, Downing KJ, Mizrahi V, Anderson R: Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis. J Antimicrob Chemother. 2006 Jan;57(1):79-84. Epub 2005 Nov 12.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
BA000043

# Drug_Target_2_GenBank_ID_Protein:
56378959

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
GK0582

# Drug_Target_2_Gene_Sequence:
>1047 bp
ATGCAACACATCGTTGATGTTCTGGTTATCGGTGCTAGTCAGGCAGGACTAGCGATGGGA
TATTATCTGAAACAAAATAATATATTGTTTGCCATTGTTGGCAAGGAAAATCGAATCGGA
GATGTTTGGAGAAACCGATATGATTCCTTAGTTCTTTTTACTCCTCGCTGGTTCAGTTCT
TTGCCAGGAATGGCTTTAAAGGGTGACCCGAACGGATATCCAACCAAGGATGAAATTGCC
GATTATTTAGAGGATTATGCTCAAAAATTTGAATTACCTATTCATCTGAACACAGAAGTC
ATTTCCCTTCAAAAAGAAGATGAGATTTTTAAAGTTACAACCAATAATGGTAATTATGTG
GCAGAGAAAGTGGTTGTAGCAACGGGTCCTTTCCAAAAGCCATACATTCCACCATTTGCA
GAAAGCTTATCCGATAAAGTGTATCAAGTGCATACATCCCGTTATTTGAATCCATCTCAA
TTACAAGAAGGCTCTGTTTTGGTAGTCGGTGCGGGAAATTCAGGGGCACAAATTGCTGTT
GAATTGTCCGAAGACAGAGAAGTTTATTTATCTGTAGGTCATAAAATGAAGTTCTTTCCA
CTTGAAATAATGGGTAAAAGTATTTTCTGGTGGTTTAAAAAATTAGGTTTATTAAATGTC
CATATCAACAGCTCGTTAGGTCAGTTTATCAGTAAGCAAAGTGACCCTATTTTCGGTAAA
GAACTGAAACATTTAATACAAGAAGGCAAAATTAAAATTAAACCCAGAACAGAAAGTATT
TTAGGAGATGTTATTTCTTTTGCAGATAACAGTCAAATTCAAGTTCAAAATGTCATTTGG
GCAACTGGATTTTATTCTGATTACAGTTGGATTCAAATTCCGAATGTTTTAGACCATAGA
GGAAAGCCCATTCACCAAAGAGGGGTAACTTCTGTGAAAGGATTGTACTTCTTGGGATTG
CCGTGGCAGTATCGAAGGGGATCTGCTCTTATTGGAGGAGTGGGTGCCGATGCAGAGTAT
TTGATAAATGATATTTTAAACCATTGA

# Drug_Target_2_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
683

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
39137

# Drug_Target_2_Name:
Potassium transporter

# Drug_Target_2_Number_of_Residues:
348

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF03486	HI0933_like

# Drug_Target_2_Protein_Sequence:
>Potassium transporter
MQHIVDVLVIGASQAGLAMGYYLKQNNILFAIVGKENRIGDVWRNRYDSLVLFTPRWFSS
LPGMALKGDPNGYPTKDEIADYLEDYAQKFELPIHLNTEVISLQKEDEIFKVTTNNGNYV
AEKVVVATGPFQKPYIPPFAESLSDKVYQVHTSRYLNPSQLQEGSVLVVGAGNSGAQIAV
ELSEDREVYLSVGHKMKFFPLEIMGKSIFWWFKKLGLLNVHINSSLGQFISKQSDPIFGK
ELKHLIQEGKIKIKPRTESILGDVISFADNSQIQVQNVIWATGFYSDYSWIQIPNVLDHR
GKPIHQRGVTSVKGLYFLGLPWQYRRGSALIGGVGADAEYLINDILNH

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Q5L2G3

# Drug_Target_2_SwissProt_Name:
CZCO_GEOKA

# Drug_Target_2_Synonyms:
Trk family

# Drug_Target_2_Theoretical_pI:
7.37

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00845
